Antibody-TLR3 agonist-conjugates program the tumor microenvironment and induce immune responses leading to tumor regression in experimental EGFRvIII-positive glioma

Biomedicine & Pharmacotherapy · Elsevier

Аннотация

Publication date: November 2026 Source: Biomedicine & Pharmacotherapy, Volume 204 Author(s): Alexander Hagstotz, Isabell Schau, Michael Seifert, Duran Sürün, Stefan Zimmermann, Frank Buchholz, Luise Rupp, Rebekka Wehner, Marc Schmitz, Gabriele Schackert, Ilker Eyüpoglu, Achim Temme

Читать у издателя →

Похожие статьи